Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

416 trials

NCT04322318
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Phase 2 · Australia, Canada, New Zealand, Puerto Rico, Saudi Arabia, United States · 205 sites
Registry update: 25 Aug 2026
NCT03844399
Recruiting
(3D) Ultrasound Imaging Liver and Kidney
Not applicable · Canada · 1 site
Registry update: 20 Jul 2025
NCT03741426
Recruiting
WIRE - Novel Treatments in Renal Cell Cancer
Phase 2 · United Kingdom · 7 sites
Registry update: 25 Sept 2026
NCT03977571
Recruiting
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
Not applicable · Denmark, Finland, Norway, Sweden · 11 sites
Registry update: 23 Sept 2026
NCT04299646
Recruiting
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Phase 2 · France · 30 sites
Registry update: 13 Jan 2026
NCT04423484
Recruiting
Therapeutic Recommendations for Nephroblastoma
Not applicable · Burkina Faso, Congo - Kinshasa, Côte d’Ivoire, Madagascar, Mali, Senegal · 7 sites
Registry update: 2 Mar 2026
NCT05218811
Recruiting
Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach
Not applicable · United States · 1 site
Registry update: 26 Jan 2023
NCT04510129
Recruiting
A Multicenter Cancer Biospecimen Collection Study
Not applicable · United States · 1 site
Registry update: 12 Mar 2025
NCT04053855
Recruiting
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Not applicable · France · 1 site
Registry update: 6 May 2026
NCT04198766
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Phase 1/2 · South Korea, Singapore, Taiwan, United States · 60 sites
Registry update: 6 Nov 2026
NCT04197414
Recruiting
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Not applicable · South Korea · 1 site
Registry update: 13 Dec 2019
NCT04115254
Recruiting
Stereotactic Magnetic Resonance Guided Radiation Therapy
Not applicable · United States · 2 sites
Registry update: 13 Nov 2025
NCT04113486
Recruiting
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
Not applicable · China · 1 site
Registry update: 29 Jul 2026
NCT04623502
Recruiting
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
Not applicable · United States · 1 site
Registry update: 28 Jan 2026
NCT03972657
Recruiting
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Phase 1/2 · South Korea, United States · 27 sites
Registry update: 4 Nov 2026
NCT03786796
Recruiting
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Phase 2 · United States · 1 site
Registry update: 30 Mar 2026
NCT03866382
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 · Puerto Rico, United States · 582 sites
Registry update: 12 Nov 2026
NCT03414827
Recruiting
Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma
Not applicable · Denmark · 1 site
Registry update: 30 Jan 2024
NCT03857373
Recruiting
Renal Cancer Detection Using Convolutional Neural Networks
Not applicable · Denmark · 1 site
Registry update: 30 Jan 2024
NCT06889649
Recruiting
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Phase 2 · China · 1 site
Registry update: 21 Mar 2025

Ordered by registry start date. Freshness and sponsorship never change the order.